Differential complementation of Bcr-Abl point mutants with c-Myc.

A complementation strategy was developed to define the signaling pathways activated by the Bcr-Abl tyrosine kinase. Transformation inactive point mutants of Bcr-Abl were tested for complementation with c-Myc. Single point mutations in the Src-homology 2 (SH2) domain, the major tyrosine autophosphorylation site of the kinase domain, and the Grb-2 binding site in the Bcr region impaired the transformation of fibroblasts by Bcr-Abl. Hyperexpression of c-Myc efficiently restored transformation activity only to the Bcr-Abl SH2 mutant. These data support a model in which Bcr-Abl activates at least two independent pathways for transformation. This strategy may be useful for discerning signaling pathways activated by other oncogenes.

[1]  Nanxin Li,et al.  BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein , 1993, Cell.

[2]  A. Cherniack,et al.  Binding of the Ras activator son of sevenless to insulin receptor substrate-1 signaling complexes. , 1993, Science.

[3]  Nanxin Li,et al.  The function of GRB2 in linking the insulin receptor to Ras signaling pathways. , 1993, Science.

[4]  Julian Downward,et al.  Epidermal growth factor regulates p21 ras through the formation of a complex of receptor, Grb2 adapter protein, and Sos nucleotide exchange factor , 1993, Cell.

[5]  D. Bar-Sagi,et al.  Grb2 mediates the EGF-dependent activation of guanine nucleotide exchange on Ras , 1993, Nature.

[6]  Nanxin Li,et al.  Guanine-nucleotide-releasing factor hSos1 binds to Grb2 and links receptor tyrosine kinases to Ras signalling , 1993, Nature.

[7]  T. Pawson,et al.  The SH2 and SH3 domains of mammalian Grb2 couple the EGF receptor to the Ras activator mSos1 , 1993, Nature.

[8]  R. Weinberg,et al.  Association of Sos Ras exchange protein with Grb2 is implicated in tyrosine kinase signal transduction and transformation , 1993, Nature.

[9]  G. Rubin,et al.  An SH3-SH2-SH3 protein is required for p21 Ras1 activation and binds to sevenless and Sos proteins in vitro , 1993, Cell.

[10]  E. Hafen,et al.  A Drosophila SH2-SH3 adaptor protein implicated in coupling the sevenless tyrosine kinase to an activator of Ras guanine nucleotide exchange, Sos , 1993, Cell.

[11]  K. Kinzler,et al.  The multistep nature of cancer. , 1993, Trends in genetics : TIG.

[12]  T. Pawson,et al.  SH2-containing phosphotyrosine phosphatase as a target of protein-tyrosine kinases. , 1993, Science.

[13]  O. Witte,et al.  SH1 domain autophosphorylation of P210 BCR/ABL is required for transformation but not growth factor independence , 1993, Molecular and cellular biology.

[14]  D. Baltimore,et al.  Crystal structure of the phosphotyrosine recognition domain SH2 of v-src complexed with tyrosine-phosphorylated peptides , 1993, Nature.

[15]  T. Pawson,et al.  Shc proteins are phosphorylated and regulated by the v-Src and v-Fps protein-tyrosine kinases. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[16]  C. Sawyers,et al.  Dominant negative MYC blocks transformation by ABL oncogenes , 1992, Cell.

[17]  A. Ullrich,et al.  The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling , 1992, Cell.

[18]  M. Moran,et al.  Molecular cloning and nucleic acid binding properties of the GAP-associated tyrosine phosphoprotein p62 , 1992, Cell.

[19]  J. Blenis,et al.  ras mediates nerve growth factor receptor modulation of three signal-transducing protein kinases: MAP kinase, Raf-1, and RSK , 1992, Cell.

[20]  Sheila M. Thomas,et al.  Ras is essential for nerve growth factor- and phorbol ester-induced tyrosine phosphorylation of MAP kinases , 1992, Cell.

[21]  D. Baltimore,et al.  Point mutations in the abl SH2 domain coordinately impair phosphotyrosine binding in vitro and transforming activity in vivo , 1992, Molecular and cellular biology.

[22]  S. Shurtleff,et al.  Myc rescue of a mutant CSF-1 receptor impaired in mitogenic signalling , 1991, Nature.

[23]  T Pawson,et al.  SH2 and SH3 domains: elements that control interactions of cytoplasmic signaling proteins. , 1991, Science.

[24]  D. Lowy,et al.  Suppression of src transformation by overexpression of full-length GTPase-activating protein (GAP) or of the GAP C terminus , 1991, Molecular and cellular biology.

[25]  O. Witte,et al.  BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive human leukemias , 1991, Molecular and cellular biology.

[26]  H. Varmus,et al.  SH2 mutants of c-src that are host dependent for transformation are trans-dominant inhibitors of mouse cell transformation by activated c-src. , 1990, Genes & development.

[27]  H. Varmus,et al.  A mutation in v-src that removes a single conserved residue in the SH-2 domain of pp60v-src restricts transformation in a host-dependent manner , 1989, Journal of virology.

[28]  S. Smith,et al.  Expression of a distinctive BCR-ABL oncogene in Ph1-positive acute lymphocytic leukemia (ALL). , 1988, Science.

[29]  E. Canaani,et al.  Fused transcript of abl and bcr genes in chronic myelogenous leukaemia , 1985, Nature.